DPBL.PK

[evgeny05]

HI

Specul. 

[evgeny05]

Hi

217.45 million shares outstanding

Deep Blue, Inc. is an organization that is bringing to market a patent-pending treatment, (Application Number 11/208,402), for HIV /AIDS and other viral infectious diseases. Deep Blue's protocols and technology have been in development for over 9 years. In April 2005, Deep Blue Inc. was granted the only FDA Non-significant Risk Status for the treatment of AIDS and Hepatitis C using class "A" medical devices.The FDA Stage-II single-site study has been approved to conduct human trials and is scheduled to be completed by January 30, 2007. Deep Blue, Inc. will complete their multi-site trials at several leading research hospitals in the first quarter of 2007.

http://www.deepblueinc.com/index.html

[pompano]

663,000 x .003  =   $1989.00     

I have got to tell you evgeny, I am extremley baffled on this one.  I mean, not even $2000 dollars worth of equity was traded in this stock today...

[evgeny05]

Hi

[evgeny05]

HI

[evgeny05]

 News & Alerts


DPBL: Short Interest DN 91.8% to 4.5K in Jun 2007

Tuesday , June 26, 2007 16:35ET

According to new short interest data from OTCBB.com, short interest for Deep Blue, Inc. (OTC: DPBL) DECREASED 91.8% to 4,486 shares for the month ended mid-June, 2007.

SYMBOL               MAY            JUNE          CHANGE       %CHANGE  DAYS/COVER
--------   -------------   -------------   -------------  ------------  ----------
DPBL              54,840           4,486         -50,354       -91.82%           1
Based on DPBL's 20-day average daily share volume of 104,818, it would require approximately 1 day(s) of buying to cover this short interest.




www.streetinvesting.com: Deep Blue Inc. Receives Progressive Following

Wednesday, June 27, 2007 04:09ET

Jun 27, 2007 (M2 PRESSWIRE via COMTEX) -- Streetinvesting.com is the leading online financial newsletter community with thousands of investors from around the world. Our goal is to bring our theories and techniques to investors seeking a different and unique approach to investment ideas. We have a research team that has been built upon the premise of finding companies that we feel may interest investors looking for that unique and tactical edge.

Please visit www.Streetinvesting.com for the full report, additional research and related articles on the company mentioned herein.

Wall Street opened with a lump of volatility disseminating words of caution about the effects of the housing sector's poor performance report for May. Investors would be keeping a low profile or at the extreme go on bear mode as The Federal Reserve meeting is closing in. With analysts pointing at an ominous augury regarding a third-quarter reading for the housing industry, investors' sentiment would be throbbing for some argumentatively positive economic data. The reality is somewhat vicious right now as the Conference Board is expected to issue its June consumer confidence index which is may well indicate a downwards tendency. As the Standard & Poor's home price index for April reached its lowest level since 1991, Deep Blue Inc. (PINKSHEETS: DPBL) closed at $ 0.003 with a trading volume of 6,395 this Tuesday.

With the world economy always in effervescence and exchanges in the US and Canada engaged in a permanent battle of nerves, our research crew is at all times digging for prospective information on the Pinksheets regarding appealing companies. We have selected Deep Blue Inc. and would be showing you their latest news underneath.

In a press release made on Tuesday June 26th 2007, Deep Blue Inc. provided some instructive insights which tickled our curiosity. Deep Blue, Inc. explained patent application progress.

Deep Blue Inc. received its first office action memorandum from the Patent and Trade Office on April 4th, 2007. Deep Blue Inc. has resubmitted its patent application in light of the material upon which this action rejected Deep Blue Inc.'s application in the first place.

Deep Blue Inc.'s CEO, Matthew Johnson, states, "Our patent application was rejected based on four separate prior patents, namely those of Reneau, Mault, Song and Nelson. While this first Office Action is unfortunate, it is also very exciting. It is within this rejection that we see substantial differences between the claims of the other inventions and ours. We have submitted our response and now are eagerly awaiting the second Office Action. This action may very well bring a rejection as well as we continue to refine, and define our technology. We believe that we are prudently moving this technology forward, and will pay careful attention to the PTO's reasoning."

Deep Blue, Inc. (www.deepblueinc.com) is bringing to market an innovative patent-pending treatment, (Application Number 11/208,402), for HIV/AIDS and other viral infectious diseases. Deep Blue's protocols and technology have been in development for over 9 years. In April 2005, Deep Blue Inc. was granted the only FDA Non-significant Risk Status for the treatment of AIDS and Hepatitis C using class "A" medical devices. The FDA Stage-II single-site study has been approved to conduct human trials and is scheduled to be completed by January 30, 2007. Deep Blue, Inc. will complete their multi-site trials at several leading research hospitals in the first quarter of 2007.

The Street has locked all its senses on the Federal Reserve's inflation verdict as this could mean a cut or hike in interest rate along the road this year. With investors on the edge and market makers rubbing their foreheads, we are carefully looking into Deep Blue Inc. future announcements. If you are interested to follow up on Deep Blue Inc. then simply visit www.streetinvesting.com and get free access to information about this company online.

Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.

We have initiated this news release as a tool to keep investors informed about the market. The information contained herein comes from an unbiased perspective and we do not have a vested interest in the companies mentioned in this release. Becoming a member to www.streetinvesting.com will give you access to all the on-going information and investment news that we come across.

Investors wishing to seek a different approach to their investment theories and concepts and to be informed of unique investment opportunities should also visit www.streetinvesting.com for a free membership.

About Street Investing






Deep Blue, Inc. Explains Funding Progress

Thursday , June 28, 2007 09:30ET


LAS VEGAS, NV -- (MARKET WIRE) -- 06/28/07 -- Deep Blue, Inc. (PINKSHEETS: DPBL) explains funding progress.

Deep Blue, Inc. is currently in the mid to final stages of negotiations with three separate funding sources. All of the funding sources have requested anonymity and Deep Blue, Inc. will honor that request. All three entities are also requesting an equity, not debt, position within the company. Deep Blue, Inc. is amenable to that condition and will welcome their teams into our family when negotiations are concluded. Deep Blue, Inc., at its sole discretion may elect to take all three sources or any combination of funding sources based on what is best for the company.

Deep Blue, Inc.'s CEO, Matthew Johnson and President, Kevin Kendrick issued a joint statement: "Deep Blue, Inc. will retain control of the company regardless of the funding source or sources and do so with minimal, if any shareholder dilution; however, it is the philosophy of this board to surround ourselves with world class people, and the personnel that we are partnering with are powerhouses in the fields of business, technology, research and development, law, advertising and marketing and health care. Building this kind of quality takes an inordinate amount of time. To ensure the well-being of those with whom we will treat with our medical technologies, both current and future, it is vital that we lay a very solid foundation before moving forward. We appreciate everyone's patience. It has, and continues to be a long and complicated process. We are continuing forward."

Deep Blue, Inc. (www.deepblueinc.com) is bringing to market an innovative patent-pending treatment, (Application Number 11/208,402), for HIV /AIDS and other viral infectious diseases.

Cautionary Statement:

[evgeny05]

Hi
+70% 

[evgeny05]

Hi

[evgeny05]

Hi

[evgeny05]

Hi